Genzyme related Press Releases
Genzyme Announces FDA Approval of Framingham Manufacturing Plant
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the Food and Drug Administration (FDA) has approved its manufacturing plant in Read more...
Genzyme Announces European Approval of Framingham Manufacturing Plant
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the European Medicines Agency (EMA) has approved its manufacturing plant in Read more...
Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires
CAMBRIDGE, Mass., Dec. 22, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration), the only biopharmaceutical company focused exclusively on the development and commercialization of Read more...
Genzyme Reports Top-line Results for TENERE Study of Oral Teriflunomide in Relapsing Multiple Sclerosis
Genzyme Reports Top-line Results for TENERE Study of Oral Teriflunomide in Relapsing Multiple Sclerosis Paris, France - December 20, 2011 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Read more...
Micromet Appoints Joseph Lobacki Senior Vice President and Chief Commercial Officer
ROCKVILLE, Md.--(BUSINESS WIRE)-- Micromet, Inc. (NASDAQ: MITI) today announced the appointment of Joseph Lobacki as Senior Vice President and Chief Commercial Officer. Mr. Lobacki brings to Micromet Read more...
Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration to Discover New CF Drugs
Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration to Discover New CF Drugs New effort will search for potential therapies targeting the most common mutation of cystic Read more...
Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration to Discover New CF Drugs
New effort will search for potential therapies targeting the most common mutation of cystic fibrosis CAMBRIDGE, Mass. & BETHESDA, Md.--(BUSINESS WIRE)-- Genzyme, a Sanofi company (EURONEXT: SAN Read more...
Genzyme Corporation (GENZ) MS Drug Significantly Reduces Relapse, Disability in Phase III Trial
Genzyme Corporation (GENZ) MS Drug Significantly Reduces Relapse, Disability in Phase III Trial 11/14/2011 7:03:18 AM CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme, a Sanofi company (EURONEXT: SAN and Read more...
Genzyme Appoints Leaders for Multiple Sclerosis and Rare Disease Businesses
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today the appointment of William “Bill” Sibold as Head of Multiple Sclerosis and Rogério Vivaldi Read more...
BioMarin to Present at the Credit Suisse Healthcare Conference
NOVATO, Calif., Nov. 3, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development at BioMarin, will present a Read more...
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
